Deutsch
 
Hilfe Datenschutzhinweis Impressum
  DetailsucheBrowse

Datensatz

DATENSATZ AKTIONENEXPORT
  Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: A long-range point of view beyond 2020

Hampel, H., Lista, S., Teipel, S. J., Garaci, F., Nistico, R., Blennow, K., et al. (2014). Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: A long-range point of view beyond 2020. Biochemical Pharmacology, 88(4), 426-449. doi:10.1016/j.bcp.2013.11.009.

Item is

Dateien

einblenden: Dateien
ausblenden: Dateien
:
Hampel.pdf (Verlagsversion), 743KB
Name:
Hampel.pdf
Beschreibung:
-
OA-Status:
Sichtbarkeit:
Öffentlich
MIME-Typ / Prüfsumme:
application/pdf / [MD5]
Technische Metadaten:
Copyright Datum:
-
Copyright Info:
© 2014 Elsevier B.V.
Lizenz:
-

Externe Referenzen

einblenden:

Urheber

einblenden:
ausblenden:
 Urheber:
Hampel, H., Autor
Lista, S., Autor
Teipel, S. J., Autor
Garaci, F., Autor
Nistico, R., Autor
Blennow, K., Autor
Zetterberg, H., Autor
Bertram, L.1, Autor           
Duyckaerts, C., Autor
Bakardjian, H., Autor
Drzezga, A., Autor
Colliot, O., Autor
Epelbaum, S., Autor
Broich, K., Autor
Lehericy, S., Autor
Brice, A., Autor
Khachaturian, Z. S., Autor
Aisen, P. S., Autor
Dubois, B., Autor
Affiliations:
1Neuropsychiatric Genetics (Lars Bertram), Dept. of Vertebrate Genomics (Head: Hans Lehrach), Max Planck Institute for Molecular Genetics, Max Planck Society, ou_1479655              

Inhalt

einblenden:
ausblenden:
Schlagwörter: Alzheimer's disease; CSF/blood biomarkers; Clinical trials; PET imaging markers; Structural/functional MRI markers
 Zusammenfassung: Recent advances in understanding the molecular mechanisms underlying various paths toward the pathogenesis of Alzheimer's disease (AD) has begun to provide new insight for interventions to modify disease progression. The evolving knowledge gained from multidisciplinary basic research has begun to identify new concepts for treatments and distinct classes of therapeutic targets; as well as putative disease-modifying compounds that are now being tested in clinical trials. There is a mounting consensus that such disease modifying compounds and/or interventions are more likely to be effectively administered as early as possible in the cascade of pathogenic processes preceding and underlying the clinical expression of AD. The budding sentiment is that "treatments" need to be applied before various molecular mechanisms converge into an irreversible pathway leading to morphological, metabolic and functional alterations that characterize the pathophysiology of AD. In light of this, biological indicators of pathophysiological mechanisms are desired to chart and detect AD throughout the asymptomatic early molecular stages into the prodromal and early dementia phase. A major conceptual development in the clinical AD research field was the recent proposal of new diagnostic criteria, which specifically incorporate the use of biomarkers as defining criteria for preclinical stages of AD. This paradigm shift in AD definition, conceptualization, operationalization, detection and diagnosis represents novel fundamental opportunities for the modification of interventional trial designs. This perspective summarizes not only present knowledge regarding biological markers but also unresolved questions on the status of surrogate indicators for detection of the disease in asymptomatic people and diagnosis of AD.

Details

einblenden:
ausblenden:
Sprache(n): eng - English
 Datum: 2013-11-222014-04-15
 Publikationsstatus: Erschienen
 Seiten: -
 Ort, Verlag, Ausgabe: -
 Inhaltsverzeichnis: -
 Art der Begutachtung: Expertenbegutachtung
 Identifikatoren: DOI: 10.1016/j.bcp.2013.11.009
ISSN: 1873-2968 (Electronic)0006-2952 (Print)
 Art des Abschluß: -

Veranstaltung

einblenden:

Entscheidung

einblenden:

Projektinformation

einblenden:

Quelle 1

einblenden:
ausblenden:
Titel: Biochemical Pharmacology
  Andere : Review - Part of the Special Issue: Alzheimer's Disease – Amyloid, Tau and Beyond
Genre der Quelle: Zeitschrift
 Urheber:
Affiliations:
Ort, Verlag, Ausgabe: Amsterdam, Boston : Elsevier
Seiten: - Band / Heft: 88 (4) Artikelnummer: - Start- / Endseite: 426 - 449 Identifikator: ISSN: 0006-2952
CoNE: https://pure.mpg.de/cone/journals/resource/954925384102